Syntec Optics Enables Revolutionary Photonic Biosensing for Accelerated Drug Discovery
Syntec Optics (Nasdaq: OPTX) announced its ongoing collaboration to develop advanced photonic biosensing technology for revolutionizing drug discovery and testing. The company is providing important optical manufacturing and sub-assembly processes to integrate photonic sensors into micro physiological systems (MPS), enabling real-time observation of human cell responses to drugs.
The technology aims to address high drug failure rates in clinical trials by replacing traditional animal models and lab tests with precise photonic biosensing. This advancement could potentially accelerate development timelines and reduce clinical trial costs. Program Manager Joel Lawther highlighted that Syntec's capabilities in producing small and precise optics are essential for enabling this technology, initially focusing on lung and brain tissue models.
Syntec Optics (Nasdaq: OPTX) ha annunciato la sua continua collaborazione per sviluppare una tecnologia avanzata di biosensing fotonico, destinata a rivoluzionare la scoperta e il testing dei farmaci. L'azienda sta fornendo importanti processi di produzione ottica e sub-assemblaggio per integrare sensori fotonici in sistemi microfisiologici (MPS), consentendo l'osservazione in tempo reale delle risposte delle cellule umane ai farmaci.
Questa tecnologia mira a affrontare le elevate percentuali di fallimento dei farmaci nelle sperimentazioni cliniche, sostituendo i tradizionali modelli animali e i test di laboratorio con biosensing fotonico preciso. Questo progresso potrebbe accelerare i tempi di sviluppo e ridurre i costi delle sperimentazioni cliniche. Il Program Manager Joel Lawther ha sottolineato che le capacità di Syntec nella produzione di ottiche piccole e precise sono essenziali per abilitare questa tecnologia, inizialmente concentrandosi sui modelli di tessuto polmonare e cerebrale.
Syntec Optics (Nasdaq: OPTX) anunció su colaboración continua para desarrollar una tecnología avanzada de biosensado fotónico destinada a revolucionar el descubrimiento y la prueba de medicamentos. La empresa está proporcionando importantes procesos de fabricación óptica y subensamblaje para integrar sensores fotónicos en sistemas microfisiológicos (MPS), lo que permite la observación en tiempo real de las respuestas de las células humanas a los medicamentos.
La tecnología tiene como objetivo abordar las altas tasas de fracaso de los medicamentos en los ensayos clínicos, reemplazando los modelos animales tradicionales y las pruebas de laboratorio por biosensado fotónico preciso. Este avance podría acelerar los plazos de desarrollo y reducir los costos de los ensayos clínicos. El Gerente de Programa Joel Lawther destacó que las capacidades de Syntec en la producción de ópticas pequeñas y precisas son esenciales para habilitar esta tecnología, enfocándose inicialmente en modelos de tejido pulmonar y cerebral.
Syntec Optics (Nasdaq: OPTX)는 약물 발견 및 테스트 혁신을 위한 고급 광자 생체 감지 기술 개발을 위한 지속적인 협력을 발표했습니다. 이 회사는 미세 생리학적 시스템(MPS)에 광자 센서를 통합하기 위한 중요한 광학 제조 및 하위 조립 프로세스를 제공하여 약물에 대한 인간 세포 반응을 실시간으로 관찰할 수 있게 합니다.
이 기술은 전통적인 동물 모델과 실험실 테스트를 정밀한 광자 생체 감지로 대체하여 임상 시험에서 높은 약물 실패율 문제를 해결하는 것을 목표로 하고 있습니다. 이 발전은 개발 일정 단축과 임상 시험 비용 절감을 가능하게 할 수 있습니다. 프로그램 관리자 조엘 로우더는 Syntec의 소형 및 정밀 광학 제품 생산 능력이 이 기술을 가능하게 하는 데 필수적이라고 강조하며, 초기에는 폐 및 뇌 조직 모델에 집중할 것이라고 밝혔습니다.
Syntec Optics (Nasdaq: OPTX) a annoncé sa collaboration continue pour développer une technologie avancée de biosensing photonique destinée à révolutionner la découverte et les tests de médicaments. L'entreprise fournit des processus de fabrication optique et de sous-assemblage importants pour intégrer des capteurs photoniques dans des systèmes microphysiologiques (MPS), permettant ainsi l'observation en temps réel des réponses des cellules humaines aux médicaments.
Cette technologie vise à résoudre les taux élevés d'échec des médicaments lors des essais cliniques en remplaçant les modèles animaux traditionnels et les tests en laboratoire par un biosensing photonique précis. Cette avancée pourrait potentiellement accélérer les délais de développement et réduire les coûts des essais cliniques. Le responsable de programme Joel Lawther a souligné que les capacités de Syntec à produire des optiques petites et précises sont essentielles pour permettre cette technologie, en se concentrant initialement sur les modèles de tissus pulmonaires et cérébraux.
Syntec Optics (Nasdaq: OPTX) hat seine laufende Zusammenarbeit zur Entwicklung fortschrittlicher photonischer Biosensing-Technologie angekündigt, um die Arzneimittelentdeckung und -prüfung zu revolutionieren. Das Unternehmen stellt wichtige optische Fertigungs- und Unterbauprozesse zur Verfügung, um photonische Sensoren in mikrophysiologische Systeme (MPS) zu integrieren, was die Echtzeitbeobachtung der Reaktionen menschlicher Zellen auf Medikamente ermöglicht.
Die Technologie zielt darauf ab, die hohen Arzneimittelversagensraten in klinischen Studien zu verringern, indem traditionelle Tiermodelle und Labortests durch präzises photonisches Biosensing ersetzt werden. Dieser Fortschritt könnte die Entwicklungszeiten beschleunigen und die Kosten klinischer Studien senken. Programmmanager Joel Lawther hob hervor, dass Syntecs Fähigkeiten in der Herstellung kleiner und präziser Optiken entscheidend für die Ermöglichung dieser Technologie sind, wobei der Fokus zunächst auf Lungen- und Gehirngewebemodellen liegt.
- Development of innovative technology addressing high drug failure rates in clinical trials
- Potential to reduce clinical trial costs and accelerate drug development timelines
- Strategic positioning in the growing biomedical technology sector
- None.
ROCHESTER, NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (“Syntec Optics” or the “Company”) (Nasdaq: OPTX), a leading provider of mission-critical products to advanced technology defense, biomedical, and communications equipment manufacturers, today announced its continued collaboration to enable development of a novel photonic biosensing technology poised to transform drug discovery and testing.
Syntec Optics is providing critical optical manufacturing and sub-assembly processes to image laser light into our OEM's photonic integrated circuits (PICs), enabling the integration of photonic sensors into micro physiological systems (MPS). Scientists can now observe how human cells respond to drugs in real time, significantly improving the accuracy and speed of drug development.
Our OEM’s groundbreaking approach addresses the critical challenge of high drug failure rates in clinical trials. Traditional testing methods often fail to predict human responses accurately. By replacing current animal models and lab tests with precise, real-time photonic biosensing, development timelines can be accelerated, and clinical trial costs can be lowered.
Joel Lawther, Program Manager at Syntec Optics, said, "Our advanced optical manufacturing capabilities to produce small and precise optics are essential for enabling photonic biosensing. By imaging laser light into our OEM's PICs, we are facilitating the creation of a powerful tool that will provide researchers with unprecedented insights into human cellular responses, starting with lung and brain tissue models."
By enabling the precise optical integration required for photonic biosensing, Syntec Optics is playing a vital role in shaping the future of medicine, helping to bring life-saving therapies to market faster.
About Syntec Optics
Syntec Optics Holdings, Inc. (Nasdaq: OPTX), headquartered in Rochester, NY, is one of the largest custom and diverse end-market optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for mission-critical OEMs. Syntec Optics recently launched new products, including Low Earth Orbit (LEO) satellite optics, lightweight night vision goggle optics, biomedical equipment optics, and precision microlens arrays. To learn more, visit www.syntecoptics.com.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, including certain financial forecasts and projections. All statements other than statements of historical fact contained in this press release, including statements as to the transactions contemplated by the business combination and related agreements, future results of operations and financial position, revenue and other metrics, planned products and services, business strategy and plans, objectives of management for future operations of Syntec Optics, market size, and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings including registration statement on Form S-4 filed with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.
For further information, please contact:
Tim Bechtold
Investor Relations
InvestorRelations@syntecoptics.com
SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)
FAQ
What is the new photonic biosensing technology developed by Syntec Optics (OPTX)?
How will OPTX's photonic biosensing technology impact drug development?
What specific tissue models is Syntec Optics (OPTX) initially targeting with their biosensing technology?
What is Syntec Optics' (OPTX) role in the photonic biosensing collaboration?
